You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm, Phenomix Sciences, anticipates that its test will help drive adoption of medications for obesity at a time when patients are reluctant to take them.
The project builds on a collaboration between Bio-Rad and Genetic Analysis using the GA-map clinical test for gut dysbiosis.
The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.
The assay can also be used to assess a broad range of metabolic conditions, including pancreatic tumors, liver disease, acromegaly, and others.